HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/6/H3057    most recent 00447.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Brower, G. L. Articles by Janicki, J. S. Search for Related Content PubMed PubMed Citation Articles by Brower, G. L. Articles by Janicki, J. S.

Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure

Cell and Developmental Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina

Submitted 3 May 2006 ; accepted in final form 9 February 2007

Angiotensin-converting enzyme (ACE) inhibitors represent the front-line pharmacological treatment of heart failure, which is characterized by left ventricular (LV) dilatation and inappropriate hypertrophy. The mechanism of action of ACE inhibitors is still unclear, but evidence suggests that they may act by influencing matrix metalloproteinase (MMP) activity. This study sought to determine whether ACE inhibitors can directly regulate MMP activity and whether this results in positive structural and functional adaptations to the heart. To this end, MMP-2 activity in LV tissue extracted from rats with an aortocaval (AV) fistula was assessed by in vitro incubation as well as in vivo treatment with captopril, lisinopril, or quinapril. Furthermore, LV size and function were determined in untreated AV fistula rats, AV fistula rats treated with lisinopril (3, 5, and 8 wk), and age-matched sham-operated controls. In vitro incubation with captopril, lisinopril, or quinapril significantly reduced MMP-2 activity, as did in vivo treatment. This occurred without a reduction in the available pool of MMP-2 protein. Long-term in vivo administration of lisinopril also prevented LV dilatation, attenuated myocardial hypertrophy, and prevented changes in myocardial compliance and contractility. The results herein demonstrate that ACE inhibitors prevent MMP-2 activity and, in so doing, represent a mechanism responsible for preventing the negative structural and functional changes that occur in the rat AV fistula model of heart failure.

ventricular function; ventricular dilatation; aortocaval fistula; remodeling; matrix metalloproteinase inhibition

This article has been cited by other articles:

				S. P. Levick, J. L. McLarty, D. B. Murray, R. M. Freeman, W. E. Carver, and G. L. Brower Cardiac Mast Cells Mediate Left Ventricular Fibrosis in the Hypertensive Rat Heart Hypertension, June 1, 2009; 53(6): 1041 - 1047. [Abstract] [Full Text] [PDF]

				K. T. Weber, W. B. Weglicki, and R. U. Simpson Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium Cardiovasc Res, February 15, 2009; 81(3): 500 - 508. [Abstract] [Full Text] [PDF]